Trial Profile
Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacokinetics
- Acronyms QUARTZ
- Sponsors AstraZeneca
- 19 Oct 2020 Results published in the Journal of Clinical Endocrinology and Metabolism
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.